{"entity":{"id":"akamis-bio","kind":"company","name":"Akamis Bio","aka":["Akamis Bio, Inc."],"tldr":"Akamis Bio develops cancer-killing viruses, given into a vein, that are built to carry extra immune-stimulating genes into tumours. It is focused on bowel cancer, first in locally advanced rectal cancer.","summary":"Akamis Bio develops T-SIGn therapeutics: intravenously given, tumour-selective oncolytic adenoviruses (based on a chimeric group B adenovirus, enadenotucirev) that carry transgene payloads into tumour cells. Its lead programme, NG-350A, encodes a secreted CD40 agonist antibody and is being tested with chemoradiotherapy in mismatch-repair-proficient locally advanced rectal cancer in the phase 1b FORTRESS trial (NCT06459869), which the company says is fully enrolled with topline results expected in the first half of 2027; the company reports an FDA Fast Track designation for NG-350A in this setting. NG-348, which encodes membrane-bound CD80 and an anti-CD3 single-chain antibody fragment, completed a phase 1 study in advanced epithelial tumours and is listed for metastatic colorectal cancer. A third, undisclosed programme uses T-SIGn to support CAR-T therapy in solid tumours with an undisclosed partner. In December 2024 the company announced $60 million in funding linked to a Series A Prime round led by Sedgwick Yard and a licence granting Xuanzhu Biopharma Greater China rights to NG-350A. The company has offices in Cambridge, Massachusetts and Oxford, UK.","asOf":"2026-11-04","links":[{"label":"Official website","url":"https://www.akamisbio.com/"},{"label":"Pipeline page","url":"https://www.akamisbio.com/science-pipeline/pipeline/"},{"label":"FORTRESS clinical trial page","url":"https://www.akamisbio.com/patient-community/clinical-trials/"},{"label":"Press release: $60 million Series A Prime and Xuanzhu licence (17 Dec 2024)","url":"https://www.akamisbio.com/news/akamis-bio-announces-60-million-in-funding-linked-to-series-a-prime-financing-and-new-strategic-partnership/"},{"label":"Press release: NG-348 phase 1 data at SITC 2026 (3 Nov 2026)","url":"https://www.akamisbio.com/news/akamis-bio-to-present-data-from-a-phase-1-study-of-ng-348-in-patients-with-advanced-epithelial-tumors-at-sitc-2026/"},{"label":"ClinicalTrials.gov NCT06459869 (FORTRESS)","url":"https://clinicaltrials.gov/study/NCT06459869"},{"label":"ARCH Venture Partners portfolio entry (archived 16 Oct 2026)","url":"https://web.archive.org/web/20261016142320/https://www.archventure.com/portfolio/"}],"tags":[],"related":[],"cancers":["rectal-cancer","colorectal"],"sections":["immunotherapy"],"technologies":["oncolytic-virus"],"targets":["cd40","cd80","cd3"],"drugs":["ng-350a","ng-348"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated on the company's site; omitted.","Secondary sources (trade press) say Akamis Bio was formerly PsiOxus Therapeutics, renamed in January 2023; the primary Business Wire release refused a script, so the former name is not added as an alias. ClinicalTrials.gov lists Akamis Bio as sponsor of enadenotucirev, NG-641 and NG-350A trials from 2012 onward.","No ClinicalTrials.gov record was found for the NG-348 phase 1 study by name search.","None of the company's trials are yet OnCo trial records, so no trials are linked.","The $60 million December 2024 figure is described by the company as funding linked to a Series A Prime financing and a licensing deal together, so it is not entered as a single equity round."],"hq":"Cambridge, MA","country":"US","companyType":"biotech","website":"https://www.akamisbio.com/","stage":"startup","investors":["arch-venture-partners"],"funding":[]},"route":"/companies/akamis-bio/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"oncolytic-virus","kind":"technology","name":"Oncolytic viruses","route":"/technologies/oncolytic-virus/"}],"target":[{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"},{"id":"cd40","kind":"target","name":"CD40","route":"/targets/cd40/"},{"id":"cd80","kind":"target","name":"CD80 (B7-1)","route":"/targets/cd80/"}],"drug":[{"id":"ng-348","kind":"drug","name":"NG-348","route":"/drugs/ng-348/"},{"id":"ng-350a","kind":"drug","name":"NG-350A","route":"/drugs/ng-350a/"}],"company":[{"id":"arch-venture-partners","kind":"company","name":"ARCH Venture Partners","route":"/companies/arch-venture-partners/"}],"trial":[{"id":"nct03852511","kind":"trial","name":"First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody)","route":"/trials/nct03852511/"},{"id":"nct06459869","kind":"trial","name":"NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer","route":"/trials/nct06459869/"},{"id":"nct05165433","kind":"trial","name":"Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)","route":"/trials/nct05165433/"}]}}